The angiotensin-receptor blocker telmisartan did no better than placebo in reducing cardiovascular events in high-risk patients intolerant to ACEs.
1 Vote(s)
ARBs not as good as ACEs
September 5, 2008
Similar Posts
- PREDICTing Heart Attacks – the 9 billion dollar question.
- Exercise is good for your brain
- Putting Guidelines into Practice
- Mediterranean Diet and Diabetes Risk
- Risky Business
